Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:36:43.805Z.
Calculation as of: 2026-10-06T15:36:43.805Z.
Quote observation: 2026-10-06T15:34:45.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e4786eb28a8a31d15cdec8f673983fbe0ec0b626c310469f8e20e074e44c13d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$740.17M
Price/FCF Ratio
N/A
TTM Avg
4.42
3Y Avg
4.41
5Y Avg
4.41
Market Cap
$725.41M
Price/FCF Ratio
N/A
TTM Avg
1186.25
3Y Avg
1180.14
5Y Avg
1180.14
Market Cap
$723.20M
Price/FCF Ratio
N/A
TTM Avg
30.96
3Y Avg
280.40
5Y Avg
522.37
Market Cap
$722.58M
Price/FCF Ratio
2.20
TTM Avg
4.81
3Y Avg
5.21
5Y Avg
6.10
Market Cap
$772.37M
Price/FCF Ratio
14.61
TTM Avg
13.25
3Y Avg
14.26
5Y Avg
22.71
Market Cap
$780.99M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | $747.44M | N/A | N/A | N/A | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $752.87M | N/A | N/A | N/A | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $740.17M | N/A | 4.42 | 4.41 | 4.41 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $725.41M | N/A | 1186.25 | 1180.14 | 1180.14 |
| Design Therapeutics, Inc. (DSGN)vs › | $770.72M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $723.20M | N/A | 30.96 | 280.40 | 522.37 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $722.58M | 2.20 | 4.81 | 5.21 | 6.10 |
| Mesa Laboratories, Inc. (MLAB)vs › | $772.37M | 14.61 | 13.25 | 14.26 | 22.71 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $780.99M | N/A | N/A | N/A | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $713.63M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
